P2 of RMT in Combo w Durvalumab or Durva + Chemo in Untreated Adenocarcinoma NSCLC

Conditions:   Adenocarcinoma of Lung;   Lung Cancer Interventions:   Drug: A: Oral Restorative Microbiota Therapy (RMT) Capsules;   Drug: B: Oral Restorative Microbiota Therapy (RMT) Capsules;   Drug: A: Durvalumab 1500 mg IV;   Drug: B: Durvalumab 1500 mg IV;   Drug: B: Cisplatin/pemetrexed or Carboplatin/pemetrexed Sponsor:   Masonic Cancer Center, University of Minnesota Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials